Granules India Limited announces US FDA approval of Naproxen Sodium and Diphenhydramine Hydrochloride Tablets, 220 mg/25 mg (OTC)

Granules India Limited announced today that the US Food & Drug Administration (US FDA) has approved its Abbreviated New Drug Application (ANDA) for Naproxen Sodium and Diphenhydramine Hydrochloride Tablets, 220 mg/25 mg (OTC), generic equivalent of Aleve PM Tablets, 220 mg/25 mg, of Bayer HealthCare LLC.

Naproxen Sodium and Diphenhydramine Hydrochloride Tablets are used for relief of occasional sleeplessness associated with minor aches and pains and to help you fall asleep and stay asleep.

Granules now has a total of 31 ANDA approvals from US FDA (29 Final approvals and 2 tentative approvals).

Aleve® PM is a registered trademark of Bayer HealthCare LLC.

Shares of GRANULES INDIA LTD. was last trading in BSE at Rs.361 as compared to the previous close of Rs. 363.45. The total number of shares traded during the day was 290450 in over 7150 trades.

The stock hit an intraday high of Rs. 368 and intraday low of 350. The net turnover during the day was Rs. 105141185.

Source : Equity Bulls

Keywords